Plasticell has entered into a collaboration with GSK to use its combinatorial stem cell screening technology, CombiCult®, to optimise the directed differentiation of induced pluripotent stem cells (iPSCs) to specific blood cell lineages for use by GSK in its therapeutic research.
Under the agreement, Plasticell, a biotechnology company specialising in stem cell screening and cell therapy development, will use its CombiCult® technology to screen combinations of molecules provided by GSK to identify and optimise iPSC differentiation protocols.
Plasticell’s proprietary technology will allow the simultaneous screening of multiple iPSC lines, allowing the development of a robust protocol that is applicable across lines.
Plasticell and GSK have worked together for over a decade on various stem cell research projects. Plasticell is co-located at the Stevenage Bioscience Catalyst, an emerging cell therapy hub on the site of GSK’s Medicines Research Centre.
Plasticell’s hematopoietic cell therapy portfolio includes the expansion of hematopoietic stem cells, currently in late pre-clinical development for cell and gene therapy applications. In addition, the company is working on the manufacture of red blood cells, platelets and immune cells from iPSC.
Plasticell’s founder and Executive Chairman, Dr Yen Choo, said: “During the course of developing its therapeutic programmes, Plasticell has acquired considerable expertise in pluripotent and hematopoietic stem cells, the derivation of specific hematopoietic cell types and the use of small molecules to drive stem cell differentiation.”